Integer Holdings Corporation Securities Class Action: Investors Must File by February 9
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Lawsuit Notification: Kahn Swick & Foti reminds investors who purchased Integer shares between July 25, 2024, and October 22, 2025, to file lead plaintiff applications by February 9, 2026, to seek recovery for economic losses.
- Earnings Downgrade: On October 23, 2025, Integer disclosed a lowered full-year 2025 sales guidance of $1.840 billion to $1.854 billion, significantly below analyst expectations, with projected net sales growth of -2% to 2% for 2026, indicating slower market adoption of its products.
- Stock Price Plunge: Following the earnings warning, Integer's stock price fell by $35.22, or over 32%, from a closing price of $109.11 on October 22, 2025, to $73.89 on October 23, reflecting market pessimism regarding the company's outlook.
- Legal Context: The case, West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, alleges that the company and its executives failed to disclose material information during the class period, violating federal securities laws, which could have long-term implications for investor confidence.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 91.75 USD with a low forecast of 69.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 85.280
Low
69.00
Averages
91.75
High
140.00
Current: 85.280
Low
69.00
Averages
91.75
High
140.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
